Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access programEditta Baldini, Diana Giannarelli, Diego Signorelli et al.|Lung Cancer|2019Cited by 42
Vinorelbine plus capecitabine in salvage therapy of breast cancer. Comparison of intravenous vs oral administration of vinorelbineVito Lorusso, Corrado Manca, R. Forcignanò et al.|Journal of Clinical Oncology|2008Cited by 5